Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2013

September 30, 2013 Corporate

Nippon Shinyaku and Pfizer conclude exclusive sales promotion consignment contract regarding "Tramal® Capsule" and "NS-24" for the treatment of cancer pain and chronic pain

 Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa; “Nippon Shinyaku”) and Pfizer Japan Inc. (Headquarters: Tokyo, Japan; President: Ichiro Umeda; “Pfizer”) announced that the two companies concluded an exclusive sales promotion consignment contract in Japan for “Tramal® Capsule” (tramadol hydrochloride, “Tramal®”), a cancer pain and chronic pain treatment for which Nippon Shinyaku holds the marketing rights, as well as “NS-24” (once-daily tramadol hydrochloride), a new treatment under development by Nippon Shinyaku for the same indications.
 According to this contract, Nippon Shinyaku will commission Pfizer with the exclusive sales promotion of “Tramal®” and “NS-24” (“tramadol preparations”). While Pfizer becomes a single sales promoter as of December 1, 2013, Nippon Shinyaku will continue to act as a distributor.

 Tramal® is a nonnarcotic opioid analgesic which acts as μ-opioid receptor agonist and monoaminergic action (reuptake inhibition of noradrenaline and serotonin). Nippon Shinyaku launched it in Japan in September 2010.
 “NS-24” is a long-acting oral preparation of tramadol hydrochloride. In Japan, Nippon Shinyaku has been conducting Phase 3 trials for the indications of cancer pain and chronic pain. Contingent upon Nippon Shinyaku obtaining regulatory approval, Pfizer will promote the product on its own as well as Tramal®.

 Taking this opportunity, Nippon Shinyaku expects to see sales expansion as the Tramal® sales resource can now be diverted to other major products. With the addition of tramadol preparations to its portfolio, Pfizer will contribute more to the QOL of a larger number of patients by proactively providing additional products in the field of pain treatment, one of its focus areas.